Remission Pathways in Chronic Lyme: Chronicity Drivers, Drug Combinations, and Remission Standards

Reframing Chronic Lyme Through Terrain Dynamics, Adaptive Capacity, and IACC Systems Biology

 This paper is part of the CYNAERA Lyme Library, a systems-based resource modeling chronic Lyme across multi-domain terrain to improve diagnosis, predict flares, and guide personalized pathways to remission.

By Cynthia Adinig

Introduction

Lyme disease has traditionally been framed as a localized infectious disease caused primarily by Borrelia burgdorferi, with persistent symptoms interpreted as evidence of incomplete treatment, residual inflammation, psychosomatic amplification, or poorly defined post-infectious sequelae. While this framework proved useful for identifying acute infection and establishing early antimicrobial protocols, it has become increasingly inadequate for explaining the complexity, variability, and chronicity observed across many patients following infection. Individuals with chronic Lyme disease and post-treatment Lyme disease syndrome (PTLDS) frequently demonstrate autonomic instability, neuroinflammation, cognitive dysfunction, environmental sensitivity, mast-cell activation, exertional intolerance, vascular dysregulation, sleep disruption, and relapsing-remitting functional decline extending beyond conventional pathogen-centered models (Rebman et al., 2017; Talbot et al., 2023; Raj et al., 2020).

The growing recognition of infection-associated chronic conditions (IACCs) provides a broader and more biologically coherent framework through which Lyme disease can be understood. Increasing evidence demonstrates substantial overlap among Lyme disease, Long COVID, ME/CFS, dysautonomia, mast-cell activation disorders, and related post-infectious syndromes involving immune dysregulation, autonomic dysfunction, endothelial instability, mitochondrial strain, neuroinflammation, and maladaptive inflammatory signaling (Komaroff and Bateman, 2021; Yong, 2021; Proal and VanElzakker, 2021). These illnesses increasingly appear less like isolated disease categories and more like overlapping terrain states emerging after sufficiently destabilizing biologic triggers.

This overlap is reinforced by both clinical observation and systems modeling. The Pathos™ Pairwise Disease Similarity System demonstrated exceptionally high overlap between Lyme disease and Long COVID across autonomic dysfunction, inflammatory instability, neurocognitive impairment, exertional intolerance, and functional variability, with modeled similarity scores exceeding 90% (Adinig, 2025). Similar overlap patterns have been observed between PTLDS and ME/CFS populations, particularly in relation to post-exertional symptom amplification, orthostatic intolerance, sensory hypersensitivity, and relapsing-remitting disability (Institute of Medicine, 2015; Komaroff and Lipkin, 2021). These findings suggest that many current diagnostic silos may reflect historical administrative divisions more than underlying biologic architecture.

At the same time, conventional therapeutic models frequently assume relatively stable physiologic baselines, predictable medication tolerance, and linear recovery trajectories following pathogen reduction. Chronic Lyme populations routinely violate these assumptions. Patients often demonstrate fluctuating medication tolerance, delayed crashes following exertion, autonomic volatility, environmental hypersensitivity, inflammatory amplification, and variable response to identical therapies depending on cumulative physiologic load, sleep architecture, hormonal state, and environmental burden (Afrin et al., 2020; Keller et al., 2021). These patterns suggest that treatment response depends not only on the intervention itself, but also on the terrain state receiving the intervention.

This paper introduces Lyme Remission Architecture™ as a systems-based framework for understanding chronic Lyme disease and PTLDS within the broader biology of infection-associated chronic conditions. The model brings together CYNAERA frameworks including Stage Zero™, Primary Chronic Trigger™ (PCT), Unified Network Collapse Theory™ (UNCT™), Biological Adaptive Reduction State™ (BARS™), Pathos™, CDF-Lyme™, BST™, TIF-L™, VitalGuard™, and the CYNAERA Remission Standard™.

Together, these tools reframe chronic Lyme disease as a dynamic terrain condition rather than a fixed infectious endpoint. In this framework, remission is not defined only by temporary symptom reduction. It is defined by restoration of adaptive capacity, autonomic flexibility, environmental tolerance, resilience, and durable system stability under real-world conditions.

CYNAERA Terrain and Remission Architecture™: From Collapse to Adaptive Recovery

Traditional Lyme disease models frequently assume that infection alone explains both illness onset and long-term outcome. Within this interpretation, Borrelia burgdorferi functions as the primary explanatory mechanism for downstream pathology, while differences in recovery are attributed primarily to microbial burden, treatment timing, or unexplained individual variability. However, growing evidence across Lyme disease, PTLDS, Long COVID, ME/CFS, dysautonomia, MCAS, and autoimmune overlap syndromes demonstrates that patients do not enter infectious events from equivalent biologic baselines, nor do they progress through chronic illness according to purely linear pathogen-driven trajectories (Hickie et al., 2006; Raj et al., 2020; Komaroff and Lipkin, 2021). Instead, chronic post-infectious illness appears to emerge through progressive terrain destabilization involving interacting autonomic, inflammatory, neuroimmune, vascular, metabolic, endocrine, and environmental systems.

This progression begins before overt chronic illness becomes clinically recognizable. Stage Zero™ defines a preclinical terrain condition in which latent instability, reduced adaptive reserve, compensatory dysfunction, or heightened physiologic vulnerability already exist prior to overt collapse (Adinig, 2025). Individuals operating within Stage Zero™ may appear healthy according to conventional medical standards while simultaneously demonstrating subtle signs of autonomic strain, inflammatory hypersensitivity, exercise intolerance, migraine patterns, viral reactivation susceptibility, connective tissue fragility, gastrointestinal dysregulation, environmental sensitivity, unexplained tachycardia, or hormonal volatility (Theoharides et al., 2015; Blitshteyn and Whitelaw, 2021). These vulnerabilities may remain partially compensated until a sufficiently disruptive event exceeds available adaptive reserve.

Primary Chronic Trigger™ (PCT) defines this destabilizing event. A PCT is not simply an infection or acute illness episode. It is a sufficiently disruptive physiologic stressor capable of pushing a biologic system beyond its adaptive threshold, initiating persistent alterations in autonomic regulation, inflammatory signaling, endothelial stability, mitochondrial function, neuroimmune coordination, and environmental tolerance (Adinig, 2025). In Lyme disease, this destabilization may involve microbial burden itself alongside inflammatory amplification, mast-cell activation, vascular dysfunction, microbiome disruption, autonomic stress, co-infection burden, and prolonged cumulative physiologic load (Jutras et al., 2019; Embers et al., 2017; Talbot et al., 2023).

Unified Network Collapse Theory™ (UNCT™) explains how this destabilization evolves into chronic multi-system dysfunction. Following a sufficiently disruptive trigger, coordination across interacting biologic systems begins to degrade recursively. Immune regulation destabilizes, autonomic flexibility narrows, endothelial responsiveness weakens, mitochondrial efficiency declines, neuroinflammatory amplification increases, vascular control deteriorates, endocrine signaling fluctuates, and metabolic reserve decreases. These disruptions reinforce one another progressively, reducing the system’s ability to maintain coordinated adaptation under cumulative stress (Komaroff and Bateman, 2021; Proal and VanElzakker, 2021).

Following this collapse process, the system transitions into Biological Adaptive Reduction State™ (BARS™), a constrained operating condition in which adaptive capacity becomes reduced relative to cumulative physiologic load (Adinig, 2026). Patients operating within BARS™ retain partial functionality but lose substantial buffering reserve, meaning that activities, medications, environmental exposures, cognitive demand, infections, sleep disruption, hormonal fluctuation, or inflammatory stimuli previously tolerated may now trigger disproportionate destabilization. This framework helps explain hallmark features observed across chronic Lyme and related IACC populations, including delayed crashes after exertion, fluctuating medication tolerance, environmental hypersensitivity, autonomic volatility, sensory amplification, and relapsing-remitting instability (Keller et al., 2021; Geng et al., 2024).

Within BARS™, stability is governed by the relationship between adaptive capacity and cumulative physiologic load:

Where: S = Stability State C = Adaptive Capacity L = Total Physiologic Load

Adaptive capacity includes autonomic regulation, mitochondrial reserve, immune resilience, endothelial stability, metabolic flexibility, endocrine coordination, and neuroimmune control. Total physiologic load includes infection burden, inflammatory signaling, environmental exposure, sleep disruption, cognitive stress, hormonal fluctuation, pharmacologic strain, and exertional demand.

Within CYNAERA architecture, environmental burden is further operationalized through VitalGuard™, an environmental load modeling framework designed to evaluate how air quality, mold exposure, humidity fluctuation, wildfire smoke, particulate matter, temperature instability, allergens, and climate-linked exposure conditions influence adaptive reserve, autonomic stability, inflammatory amplification, and flare probability across chronic illness populations. Rather than treating environmental exposure as a secondary lifestyle variable, VitalGuard™ conceptualizes environmental conditions as active terrain modifiers capable of directly altering treatment tolerance, symptom volatility, remission durability, and cumulative physiologic load within constrained adaptive states. 

Pathos™ extends this terrain-based framework by quantifying biologic overlap among chronic post-infectious illnesses through structured pairwise similarity modeling. Rather than classifying diseases according to historical specialty silos or initiating pathogens alone, Pathos™ evaluates conditions according to shared terrain behavior across autonomic dysfunction, neuroinflammation, inflammatory amplification, exertional intolerance, sensory instability, endocrine disruption, gastrointestinal involvement, pain burden, and functional variability (Adinig, 2025). Pairwise modeling demonstrated that Lyme disease and Long COVID exhibit similarity scores exceeding 90%, while PTLDS and ME/CFS similarly demonstrate extensive overlap across chronic systems dysfunction domains.

This terrain architecture directly informs diagnostic interpretation through Composite Diagnostic Fingerprints™ (CDF-Lyme™), which expands assessment beyond binary pathogen confirmation toward multidimensional terrain characterization. Rather than focusing solely on microbial exposure, CDF-Lyme™ integrates autonomic metrics, inflammatory burden, neurocognitive dysfunction, cardiovascular instability, mast-cell activation signatures, sensory hypersensitivity, sleep disruption, gastrointestinal dysregulation, environmental reactivity, exertional intolerance, and flare sequencing patterns into structured phenotype profiles.

Diagnostic stratification then informs treatment deployment through Bioadaptive Systems Therapeutics™ (BST™). BST™ reframes therapy as a responsive adaptive systems process rather than a static pharmaceutical event. Therapeutic response depends not only on the intervention itself, but also on timing, sequencing, cumulative physiologic load, autonomic state, inflammatory burden, environmental exposure, hormonal variability, mitochondrial reserve, and adaptive capacity at the moment treatment is introduced (Adinig, 2025). This helps explain why chronic Lyme patients frequently demonstrate dramatically different responses to identical therapies depending on flare state, sleep quality, environmental burden, infection load, or cumulative exertional strain.

Therapeutic Integration Frameworks™ (TIF-L™) operationalize this adaptive sequencing through coordinated terrain-domain intervention pathways rather than isolated symptom suppression. Within this model, treatment is organized according to active systems dysfunction across antimicrobial burden, mast-cell activation, autonomic instability, mitochondrial impairment, neuroimmune amplification, vascular dysfunction, and environmental sensitivity. Rather than assuming a singular therapeutic target, TIF-L™ recognizes that remission corridors frequently emerge through synchronized stabilization across interacting biologic domains simultaneously.

CYNAERA REPURPOSED™ extends this framework by accelerating recognition of low-cost FDA-approved, OTC, compounded, and repurposed therapies already demonstrating real-world utility across chronic illness populations. Rather than asking whether a therapy was originally designed specifically for Lyme disease, the framework evaluates whether the intervention meaningfully targets an active terrain domain contributing to systems instability. This reflects the growing therapeutic overlap observed across Lyme disease, Long COVID, ME/CFS, dysautonomia, mast-cell activation disorders, and related IACC populations.

Together, Stage Zero™, PCT™, UNCT™, BARS™, Pathos™, CDF-Lyme™, BST™, TIF-L™, and CYNAERA REPURPOSED™ form a unified terrain and remission architecture explaining how chronic Lyme disease emerges, persists, fluctuates, and responds to adaptive therapeutic intervention. Infection initiates destabilization, but terrain dynamics determine chronicity, variability, flare behavior, treatment tolerance, remission potential, and long-term resilience. Within this framework, remission reflects progressive restoration of adaptive reserve, autonomic flexibility, inflammatory resilience, environmental tolerance, exertional recovery, and durable systems stability under real-world conditions rather than transient symptom suppression alone.

Terrain-Aligned Trial Architecture™ (TATA™): Modernizing Chronic Lyme Clinical Design

Many chronic Lyme clinical trials have likely failed not because meaningful therapeutic signals were absent, but because the underlying trial architecture was fundamentally misaligned with dynamic terrain biology. Conventional clinical trial models assume relatively stable physiologic baselines, homogeneous cohorts, predictable treatment tolerance, and linear response trajectories. Chronic Lyme populations frequently violate each of these assumptions (Institute of Medicine, 2015; Rebman et al., 2017).

Patients meeting identical Lyme diagnostic criteria may demonstrate profoundly different terrain states involving autonomic instability, mast-cell activation, neuroinflammation, mitochondrial dysfunction, environmental hypersensitivity, orthostatic intolerance, cognitive impairment, or exertional intolerance. Pooling these biologically divergent populations into single undifferentiated study cohorts substantially dilutes therapeutic signal strength and increases the likelihood that meaningful phenotype-specific responses will be interpreted as statistical inconsistency or trial failure (Jason et al., 2008; Komaroff and Bateman, 2021).

Terrain-Aligned Trial Architecture™ (TATA™) was developed within CYNAERA architecture to address this limitation by replacing static symptom-only trial design with phenotype-guided systems modeling. Rather than grouping all chronic Lyme patients into singular homogeneous cohorts, TATA™ stratifies participants according to:

• autonomic phenotype

• inflammatory burden

• mast-cell activation overlap

• environmental sensitivity

• exertional intolerance severity

• neuroimmune involvement

• mitochondrial dysfunction

• adaptive reserve capacity

• cumulative physiologic load

  
  

Within TATA™, timing architecture becomes equally important. Chronic Lyme populations frequently demonstrate delayed flare dynamics and post-exertional symptom amplification occurring 24 to 72 hours after exertion, stress exposure, environmental burden shifts, or therapeutic escalation (Geng et al., 2024). Conventional trial intervals may therefore capture the wrong physiologic windows entirely. TATA™ instead integrates longitudinal monitoring, wearable physiology, autonomic metrics, sleep architecture analysis, symptom sequencing, and flare prediction timing windows aligned with SymCas™ systems modeling.

The framework also replaces static endpoint logic with terrain-responsive remission metrics. Traditional trial outcomes frequently prioritize isolated symptom reduction or laboratory normalization despite substantial ongoing instability in autonomic function, exertional tolerance, environmental sensitivity, or flare frequency. TATA™ instead evaluates:

• adaptive reserve expansion

• flare reduction durability

• exertional recovery improvement

• autonomic stability

• environmental tolerance

• cognitive resilience

• sustained functional consistency

• remission durability under real-world conditions

This approach aligns naturally with growing federal interest in adaptive trial design, real-world evidence integration, wearable health analytics, AI-assisted physiologic modeling, and patient-reported outcomes (FDA, 2023). Increasing acceptance of historical controls, longitudinal digital monitoring, and pragmatic evidence frameworks further strengthens the plausibility of terrain-aligned chronic illness trials within future Lyme and IACC modernization initiatives. Within this framework, chronic Lyme trials become adaptive systems studies rather than simplistic antimicrobial response experiments. Therapeutic success is evaluated not merely according to transient symptom reduction, but according to whether the biologic system itself demonstrates progressive restoration of coordinated adaptive stability.

Combination Logic: Terrain-Based Pharmacologic Convergence

Single-target therapies cannot reliably recalibrate a terrain state failing simultaneously across immune, autonomic, neurovascular, inflammatory, mitochondrial, and neuroglial domains. Chronic Lyme disease and PTLDS behave as coordinated systems conditions rather than isolated infectious events, meaning that meaningful remission pathways frequently require synchronized multi-axis stabilization rather than singular pharmacologic correction alone (Komaroff and Bateman, 2021; Raj et al., 2020). Within CYNAERA architecture, combination logic therefore focuses on terrain convergence, the coordinated deployment of pharmacologic, environmental, autonomic, metabolic, and behavioral interventions designed to progressively lower physiologic volatility while restoring adaptive coherence across interacting systems.

Importantly, combination architecture does not imply indiscriminate polypharmacy. Within Bioadaptive Systems Therapeutics™ (BST™), sequencing order, terrain timing, autonomic stability, inflammatory load, environmental burden, sleep architecture, and exertional state substantially influence whether a therapy stabilizes or destabilizes the system at the moment of deployment (Adinig, 2025). A mitochondrial support protocol introduced during active autonomic overdrive may worsen oxidative stress despite demonstrating benefit during stabilized autonomic windows. Similarly, antimicrobial escalation during severe mast-cell activation or inflammatory amplification may narrow physiologic reserve further rather than improve long-term recovery trajectory. Therapeutic success therefore depends not only on the intervention itself, but on whether the terrain possesses sufficient adaptive reserve to tolerate the intervention safely.

Within CYNAERA simulations, sequenced therapeutic activation reduced modeled flare probability by approximately 35% compared with simultaneous broad deployment strategies in severe chronic cohorts (CYNAERA Institute, 2025, Pathos Technical Memo). These findings support the interpretation that remission pathways may depend less on maximizing treatment intensity and more on synchronizing intervention timing with biologic readiness windows.

TIF-L1™: Immuno-Mast Cell Modulation and Inflammatory Quieting

Purpose: Reduce inflammatory amplification, mast-cell activation, endothelial destabilization, histamine signaling, and neuroimmune overactivation sufficiently to expand physiologic tolerance windows for downstream therapeutic escalation.

Emerging evidence increasingly supports overlap among PTLDS, mast-cell activation disorders, dysautonomia, Long COVID, and ME/CFS involving inflammatory hypersensitivity, endothelial dysfunction, microglial activation, histamine signaling abnormalities, and exaggerated stress response amplification (Afrin et al., 2020; Theoharides et al., 2015). Within unstable terrain states, persistent inflammatory signaling may consume substantial adaptive reserve continuously, narrowing treatment tolerance and increasing flare probability.

Potential stabilization combinations include:

• cetirizine + famotidine

• ketotifen + low-dose naltrexone (LDN)

• cromolyn sodium + DAO support

• vitamin C + mast-cell stabilization protocols

• low-histamine nutritional interventions

• inflammatory load reduction strategies

Low-dose naltrexone demonstrates mechanistic plausibility through modulation of microglial activation and neuroinflammatory signaling pathways, while H1/H2 antagonism may reduce histamine-driven vascular and autonomic amplification (Younger and Mackey, 2009; Younger et al., 2014). Stabilization within this corridor is expected to improve medication tolerance, reduce sensory hypersensitivity, lower nocturnal autonomic volatility, and improve readiness for downstream autonomic and metabolic interventions.

TIF-L2™: Autonomic Re-Synchronization and Vascular Stabilization

Purpose: Restore autonomic flexibility, cerebral perfusion stability, baroreflex responsiveness, endothelial regulation, and orthostatic tolerance while reducing sympathetic overdrive and physiologic overcompensation.

Autonomic dysfunction remains one of the most reproducible findings across chronic Lyme disease, PTLDS, Long COVID, and ME/CFS populations, particularly among patients demonstrating orthostatic intolerance, tachycardia, exercise intolerance, cognitive impairment, and delayed recovery dynamics (Raj et al., 2022; van Campen et al., 2020). Reduced cerebral blood flow during orthostatic stress has been documented repeatedly within ME/CFS cohorts and likely contributes significantly to cognitive dysfunction, fatigue amplification, sensory overload, and exertional instability (van Campen et al., 2021).

Potential autonomic stabilization combinations include:

• propranolol or ivabradine

• saline expansion protocols

• fludrocortisone

• compression therapy

• paced autonomic rehabilitation

• parasympathetic activation strategies

• endothelial stabilization support

• electrolyte optimization

Environmental integration is also critical within this corridor. Heat exposure, wildfire smoke, humidity fluctuation, particulate burden, and barometric instability substantially increase autonomic volatility within constrained terrain states (Keller et al., 2021). Pairing autonomic stabilization protocols with VitalGuard™ environmental forecasting may therefore reduce flare frequency and preserve adaptive reserve during vulnerable periods. Importantly, autonomic stabilization frequently functions as a prerequisite for successful metabolic recovery because persistent sympathetic overdrive narrows mitochondrial tolerance windows and increases oxidative stress burden continuously.

TIF-L3™: Mito-Metabolic Restoration and Energy Stabilization

Purpose: Restore mitochondrial efficiency, redox balance, ATP production stability, oxidative resilience, and exertional recovery capacity following prolonged inflammatory and autonomic strain.

Mitochondrial dysfunction and impaired metabolic flexibility are increasingly recognized across PTLDS, Long COVID, and ME/CFS populations, particularly among patients demonstrating post-exertional symptom amplification and delayed crash dynamics (Naviaux et al., 2016; Armstrong et al., 2015). Persistent autonomic stress, inflammatory signaling, endothelial dysfunction, and oxidative overload may collectively impair mitochondrial recovery capacity over time, reducing exertional tolerance and increasing physiologic fragility.

Potential metabolic restoration combinations include:

• CoQ10

• riboflavin

• magnesium glycinate

• acetyl-L-carnitine

• D-ribose

• NAD-supportive compounds

• paced metabolic loading

• oxidative stress reduction strategies

Within BST™, timing logic becomes especially important during metabolic restoration phases. Introducing mitochondrial stimulation during active inflammatory amplification or autonomic overdrive may paradoxically worsen symptom burden by increasing oxidative demand beyond available adaptive reserve. CYNAERA modeling therefore prioritizes deployment during lower-volatility recovery windows, typically 48–72 hours following resolution of major post-exertional destabilization events.

Sequencing integration with TIF-L1™ is particularly important because immune quieting frequently expands mitochondrial tolerance windows substantially. Patients unable to tolerate metabolic support during unstable inflammatory periods may tolerate identical interventions once mast-cell and autonomic amplification decline.

TIF-L4™: Neuroimmune Modulation and Neural Re-Synchronization

Purpose: Reduce neuroglial priming, neuroinflammatory persistence, sensory amplification, cognitive dysfunction, sleep fragmentation, and maladaptive neuroimmune reinforcement loops.

Persistent neuroimmune activation is increasingly recognized across chronic Lyme disease, Long COVID, and ME/CFS populations, particularly among patients demonstrating cognitive dysfunction, sensory hypersensitivity, fatigue amplification, sleep instability, migraine patterns, and prolonged post-exertional neurologic crashes (Komaroff and Lipkin, 2021). Chronic neuroglial activation may perpetuate autonomic instability, inflammatory signaling, endocrine disruption, and maladaptive stress reinforcement long after acute infectious phases resolve.

Potential neuroimmune stabilization combinations include:

• low-dose naltrexone

• palmitoylethanolamide (PEA)

• memantine

• micro-pulse corticosteroid strategies

• neuroinflammatory modulation protocols

• sleep architecture stabilization

• sensory load reduction

• circadian rhythm restoration

Importantly, neuroplasticity is not conceptualized within CYNAERA architecture as the primary driver of remission, but rather as a stabilizer of remission durability once volatility indices sufficiently decline. Following successful autonomic, inflammatory, metabolic, and environmental stabilization, the nervous system gradually begins passive recalibration toward less defensive operational states. This phase reflects biologic memory consolidation rather than psychological adaptation.

Within CYNAERA modeling, patients maintaining:

• stable sleep architecture

• lower inflammatory volatility

• safer environmental conditions

• improved autonomic flexibility

• reduced post-exertional destabilization

for sustained periods exceeding 60 days demonstrate substantially greater long-term remission durability than patients repeatedly cycling through unresolved flare states.

Together, TIF-L1™ through TIF-L4™ form the pharmacologic and systems backbone of the CYNAERA Remission Corridor™:

• inflammatory quieting

• autonomic coherence

• metabolic stabilization

• neuroimmune recalibration

When dynamically sequenced through BST™, monitored through Pathos™ volatility indices, and stabilized through environmental load reduction strategies, these corridors collectively support progressive restoration of adaptive reserve, resilience, exertional tolerance, autonomic flexibility, and durable terrain stability across chronic Lyme populations.

Simulated Multi-Mechanism Combination Therapy Response Versus Single-Therapy Response in Chronic Lyme

To illustrate why chronic Lyme disease and PTLDS may require multi-mechanism therapeutic sequencing rather than single-agent intervention alone, a simplified four-patient simulation was constructed using matched patient severity across two therapeutic models. Two hypothetical patients were modeled under single-therapy conditions, and two matched patients were modeled under multi-mechanism combination therapy conditions. Illness severity, follow-up duration, baseline access, adherence, and supportive care assumptions were held constant within each matched severity pair.

The purpose of the simulation was not to estimate exact clinical effect sizes, but to demonstrate how multi-axis treatment may produce greater cumulative improvement, later plateau formation, and more durable remission movement than single-domain therapy in patients whose illness operates across immune, autonomic, metabolic, and neuroimmune systems.

Single-therapy response was modeled as an intervention targeting only one dominant domain, such as antimicrobial activity or inflammatory reduction, without coordinated autonomic stabilization, mast-cell modulation, mitochondrial support, sleep restoration, environmental load reduction, or neuroimmune recalibration. Multi-mechanism therapy was modeled through the CYNAERA Therapeutic Integration Framework-Lyme™ (TIF-L™), combining sequenced antimicrobial terrain reduction, immuno-mast cell stabilization, autonomic support, mito-metabolic restoration, and neuroimmune modulation. The simulation assumes that chronic Lyme terrain instability is not corrected by a single mechanism when multiple interacting systems remain destabilized.

The core treatment breadth formula used was:

Treatment Breadth Score = Number of Targeted Terrain Domains × Sequencing Quality ×

Tolerance Fit.

The response framework was:

Lyme Remission Movement Index = Symptom Improvement Percent × Duration − Flare Burden × Flare Severity.

These formulas are presented as high-level interpretive frameworks for simulation and do not represent a validated clinical dosing algorithm or a complete proprietary implementation.

Four matched hypothetical patients were included. Patient A represented mild-moderate chronic Lyme treated with single therapy. Patient B represented mild-moderate chronic Lyme treated with multi-mechanism combination therapy. Patient C represented severe chronic Lyme treated with single therapy. Patient D represented severe chronic Lyme treated with multi-mechanism combination therapy. All four patients were assumed to have equivalent treatment access, adherence, pacing guidance, and follow-up. Only therapeutic breadth and baseline illness severity varied across the simulation.

Simulated Patient Conditions and Treatment Breadth

Patient	Lyme Severity	Therapeutic Model	Targeted Terrain Domains	Sequencing Quality	Tolerance Fit	Treatment Breadth Score
A	Mild-Moderate	Single Therapy	1	0.8	1.0	0.80
B	Mild-Moderate	Multi-Mechanism Combo	5	1.1	1.0	5.50
C	Severe	Single Therapy	1	0.7	0.8	0.56
D	Severe	Multi-Mechanism Combo	5	1.0	0.8	4.00

Treatment response was then simulated across a 12-week observation period. Mild-moderate patients receiving single therapy were modeled as showing early partial improvement followed by plateau once the untreated domains continued to generate physiologic load. Mild-moderate patients receiving multi-mechanism combination therapy were modeled as showing slower initial adjustment but greater cumulative improvement as immune, autonomic, metabolic, and neuroimmune stabilization began reinforcing one another. Severe patients receiving single therapy were modeled as having the weakest response and earliest plateau due to reduced adaptive reserve and ongoing untreated terrain burden. Severe patients receiving multi-mechanism combination therapy were modeled as showing slower but more meaningful improvement, with fewer destabilizing flares and a higher final remission movement score.

Simulated 12-Week Response by Therapeutic Model

Patient	Lyme Severity	Therapeutic Model	Week 12 Symptom Improvement	Flare Burden	Remission Movement Index	Plateau Timing
A	Mild-Moderate	Single Therapy	12%	3	135	Early
B	Mild-Moderate	Multi-Mechanism Combo	31%	2	368	Late
C	Severe	Single Therapy	5%	5	50	Earliest
D	Severe	Multi-Mechanism Combo	19%	3	219	Mid-Late

In this simulation, multi-mechanism combination therapy outperformed single therapy at both severity levels. The mild-moderate combination patient achieved more than twice the simulated symptom improvement of the matched single-therapy patient and reached plateau later in the observation period. The severe combination patient showed a slower but substantially stronger response than the severe single-therapy patient, suggesting that multi-axis stabilization may convert partial biologic improvement into more durable terrain movement even when baseline adaptive reserve is low.

The single-therapy patients plateaued earlier because the untreated domains continued to generate load. For example, antimicrobial activity alone may reduce one component of burden while persistent autonomic instability, mast-cell activation, sleep disruption, mitochondrial impairment, or neuroimmune volatility continues to constrain recovery. In contrast, combination therapy was modeled as lowering multiple sources of load simultaneously while expanding adaptive capacity across interacting domains. This creates a compounding effect: immune quieting improves autonomic tolerance, autonomic stabilization improves metabolic recovery, metabolic restoration supports neuroimmune recalibration, and neuroimmune stabilization improves sleep and exertional resilience.

These findings support the central hypothesis of Lyme Remission Architecture™: apparent treatment failure may occur when therapy is too narrow for the terrain being treated. A patient may appear nonresponsive to a biologically plausible intervention not because the intervention has no value, but because other destabilized systems continue to suppress visible therapeutic gain. In this model, remission movement depends less on one therapy “working” in isolation and more on whether the therapeutic architecture reduces total load while expanding adaptive reserve across multiple biologic domains.

Dynamic Dosing and Adaptive Sequencing: The Bioadaptive Systems Therapeutics™ (BST™) Model

Fixed dosing frameworks are poorly optimized for chronic Lyme disease and related IACCs because the underlying biology itself is not static. Immune signaling, autonomic stability, inflammatory amplification, endothelial responsiveness, mitochondrial function, environmental sensitivity, sleep architecture, and exertional tolerance frequently fluctuate over time, often in delayed and non-linear patterns (Komaroff and Bateman, 2021; Raj et al., 2020). Conventional treatment models generally assume that therapies can be administered according to fixed schedules independent of terrain state. However, chronic Lyme populations routinely demonstrate fluctuating medication tolerance, delayed crashes after exertion, variable inflammatory responsiveness, and alternating periods of therapeutic sensitivity and fragility (Rebman et al., 2017; Talbot et al., 2023). These patterns strongly suggest that therapeutic deployment must adapt dynamically to biologic conditions rather than rely exclusively on rigid interval-based dosing structures.

Bioadaptive Systems Therapeutics™ (BST™) was developed within CYNAERA architecture to address this limitation by translating oscillations in immune, autonomic, inflammatory, metabolic, neuroimmune, and environmental systems into adaptive treatment-response feedback loops (Adinig, 2025). Within BST™, therapies are not interpreted as isolated interventions delivered according to arbitrary fixed intervals. Instead, dosing intensity, sequencing order, timing windows, tapering strategies, and therapeutic overlap are continuously adjusted according to cumulative physiologic load, autonomic volatility, inflammatory burden, environmental exposure, recovery dynamics, and adaptive reserve capacity.

This distinction becomes particularly important within chronic Lyme populations operating in Biological Adaptive Reduction State™ (BARS™) conditions because physiologic tolerance windows may narrow dramatically during periods of autonomic overdrive, mast-cell activation, sleep disruption, inflammatory amplification, environmental burden, or post-exertional destabilization (Keller et al., 2021). A therapy tolerated during relatively stable low-volatility periods may become destabilizing during active flare states despite no change in dose or formulation. BST™ therefore reframes dosing not as a fixed pharmacologic schedule, but as a terrain-responsive systems process.

BST™ Core Architecture

BST™ organizes chronic illness treatment into four adaptive therapeutic phases:

• stabilization

• activation

• reconstruction

• maintenance

Each phase carries distinct biologic objectives, physiologic thresholds, and terrain readiness requirements.

Phase	Primary Objective	Terrain Characteristics	Therapeutic Focus
Stabilization	Reduce inflammatory volatility and autonomic overdrive	High flare probability, mast-cell activation, autonomic instability	TIF-L1™ inflammatory quieting
Activation	Sequentially introduce restorative interventions	Expanding autonomic reserve and reduced inflammatory amplification	TIF-L2™ and TIF-L3™ overlap
Reconstruction	Sustain metabolic and neuroimmune recovery	Improved exertional tolerance and lower flare frequency	Mito-metabolic restoration and neural stabilization
Maintenance	Preserve remission durability and adaptive reserve	Stable HRV, lower inflammatory burden, improved environmental tolerance	Dynamic tapering and resilience preservation

Within stabilization phases, treatment intensity is intentionally conservative because excessive early escalation may overwhelm already constrained adaptive reserve. Histamine modulation, inflammatory reduction, sleep stabilization, autonomic quieting, environmental load reduction, and pacing strategies are prioritized before aggressive metabolic or neuroimmune activation protocols are introduced.

As terrain stability improves, activation phases permit gradual therapeutic overlap between autonomic support, mitochondrial restoration, endothelial stabilization, and neuroimmune recalibration strategies. Reconstruction phases then focus on expanding exertional tolerance, reducing delayed crash frequency, restoring metabolic flexibility, and increasing resilience under real-world environmental conditions. Maintenance phases emphasize remission durability through adaptive tapering, environmental forecasting integration, autonomic preservation, and long-term flare prevention.

BST™ Algorithmic Feedback Loop

Within BST™, therapeutic adjustments are guided through adaptive physiologic feedback loops integrating autonomic metrics, inflammatory signaling, symptom volatility, recovery timing, environmental burden, and adherence stability. Rather than assuming static treatment response over time, the framework continuously recalibrates intervention timing and intensity according to biologic response trajectories.

The core BST™ adaptive dosing relationship is represented as:

Dose(t+1) = Dose(t) + (ΔHRV × Wa) − (ΔIL6 × Wi) − (SPI × Ws)

Where:

Dose(t+1) = Subsequent therapeutic intensity 

Dose(t) = Current therapeutic intensity 

ΔHRV = Change in autonomic flexibility 

ΔIL6 = Change in inflammatory signaling burden 

SPI = Socioeconomic Pressure Index™ destabilization weighting Wa, Wi, Ws = Patient-specific weighting coefficients

Within this framework, improvements in autonomic flexibility may permit cautious therapeutic expansion, while inflammatory escalation or worsening socioeconomic instability may require therapeutic reduction, pacing extension, or delayed sequencing transitions. This prevents therapies from being escalated during periods of reduced terrain tolerance merely because arbitrary dosing intervals have elapsed.

Importantly, BST™ also recognizes that non-biologic instability may significantly influence treatment outcomes. Socioeconomic volatility, housing instability, environmental exposure burden, food insecurity, medication access disruption, caregiver strain, and occupational stress may all substantially increase cumulative physiologic load and destabilization risk (Jason et al., 2008). SPI™ integration therefore helps distinguish biologic treatment failure from externally driven terrain destabilization.

The implications extend beyond chronic Lyme disease alone. Dynamic dosing architecture may become increasingly necessary across broader IACC populations because relapsing-remitting illnesses frequently violate the assumptions underlying conventional fixed treatment schedules. Chronic illness medicine therefore may require transition away from static prescribing frameworks toward adaptive systems-guided therapeutic deployment integrating wearable physiology, longitudinal symptom analysis, environmental modeling, autonomic monitoring, and predictive flare analytics directly into treatment architecture itself.

The CYNAERA Remission Standard™: Defining Durable Recovery in Chronic Lyme Disease

One of the greatest failures within chronic illness medicine has been the absence of a coherent operational definition of remission. Conventional medical frameworks frequently define improvement according to isolated symptom reduction, transient laboratory normalization, or temporary increases in functional output despite extensive evidence that chronic Lyme populations often continue to experience relapsing-remitting instability, autonomic dysfunction, inflammatory amplification, environmental hypersensitivity, exertional crashes, and neurocognitive fluctuation long after apparent treatment completion (Rebman et al., 2017; Fallon et al., 2008).

The CYNAERA Remission Standard™ was developed to address this limitation by redefining remission according to restoration of adaptive capacity and durable terrain stability rather than the temporary absence of symptoms alone. Within this framework, remission reflects measurable expansion of physiologic resilience, reduced flare probability, improved autonomic flexibility, decreased inflammatory volatility, improved environmental tolerance, improved exertional recovery, broader medication tolerance, and sustained functional durability under real-world conditions (Adinig, 2025).

This interpretation fundamentally changes how therapeutic success is evaluated. Treatments are not judged solely according to whether they transiently suppress symptoms or alter isolated biomarkers. Instead, interventions are evaluated according to whether they:

• expand adaptive reserve

• reduce cumulative physiologic load

• stabilize autonomic regulation

• improve resilience under stress

• reduce delayed crash frequency

• improve environmental tolerance

• improve durability across fluctuating real-world conditions

Within this framework, remission strengthens as adaptive reserve expands relative to cumulative load. Load includes inflammatory activation, environmental burden, sleep disruption, infection stress, autonomic strain, hormonal fluctuation, cognitive exertion, pharmacologic burden, and physical demand. Patients operating near equilibrium remain highly relapse-prone even if symptoms temporarily improve, whereas durable remission requires meaningful expansion of the adaptive buffer itself.

The CYNAERA Remission Standard™ also resolves longstanding conflicts surrounding what constitutes successful recovery in chronic Lyme disease. Many patients considered “treated” according to conventional infectious disease criteria continue to experience substantial functional impairment despite reduced microbial burden. Conversely, some patients demonstrate meaningful restoration of resilience and quality of life despite residual intermittent symptom variability. Within a terrain-based framework, remission is therefore not defined through simplistic binary distinctions between “sick” and “cured.” Instead, remission reflects progressive restoration of coordinated systems stability across autonomic, inflammatory, neuroimmune, vascular, metabolic, and environmental domains simultaneously.

This interpretation aligns closely with growing observations across Lyme disease, Long COVID, ME/CFS, dysautonomia, mast-cell activation disorders, and related IACC populations demonstrating that chronic illness recovery frequently occurs gradually through expansion of adaptive flexibility rather than through abrupt singular resolution events (Komaroff and Bateman, 2021; Yong, 2021). Chronic Lyme remission therefore becomes biologically measurable, operationally definable, and therapeutically navigable within a broader systems-based terrain framework.

Policy Implications: Lyme Disease as the Gateway to IACC Modernization

The continued fragmentation of chronic post-infectious illness into isolated disease silos has produced substantial inefficiency across research funding, therapeutic development, surveillance infrastructure, clinical guidance, insurance coverage, disability evaluation, and patient care delivery. Lyme disease, Long COVID, ME/CFS, dysautonomia, mast-cell activation disorders, and related IACCs continue to be managed through separate institutional frameworks despite extensive overlap in autonomic dysfunction, inflammatory amplification, endothelial instability, neuroimmune disruption, environmental sensitivity, exertional intolerance, and relapsing-remitting disability (Institute of Medicine, 2015; Komaroff and Lipkin, 2021). This fragmentation has contributed to duplicated clinical trials, inconsistent diagnostic standards, delayed therapeutic recognition, and prolonged disability across millions of patients globally.

Lyme disease occupies a uniquely important position within this landscape because it represents both a politically validated chronic infection model and a biologically connected gateway into broader IACC modernization. Unlike many post-infectious illnesses that remain marginalized or contested, Lyme disease has achieved growing recognition within federal health agencies, public health infrastructure, vector-borne disease surveillance systems, and bipartisan legislative discussions due to expanding prevalence, severe chronic presentations, and longstanding advocacy pressure (CDC, 2024). Simultaneously, Pathos™ modeling demonstrates extraordinary biologic overlap between Lyme disease, Long COVID, and ME/CFS terrain states, suggesting that policy modernization initiated through Lyme disease could naturally extend across the broader IACC continuum (Adinig, 2025).

This convergence creates a substantial opportunity for systems-level modernization across federal healthcare infrastructure. Rather than continuing to construct isolated research pipelines and therapeutic ecosystems for each overlapping chronic illness independently, agencies could instead develop integrated IACC frameworks centered around:

• phenotype-guided stratification

• adaptive trial architecture

• real-world evidence integration

• wearable physiology

• environmental modeling

• therapeutic repurposing

• autonomic stabilization

• longitudinal symptom sequencing

• AI-assisted flare prediction

• remission durability analysis

Such an approach would substantially reduce duplication while accelerating therapeutic recognition and deployment across multiple chronic illness populations simultaneously.

The current regulatory environment increasingly supports the plausibility of accelerated modernization pathways. FDA expansion of real-world evidence frameworks, adaptive trial models, patient-reported outcome integration, AI-assisted analytics, and historical control acceptance collectively suggest movement away from rigid one-size-fits-all development paradigms (FDA, 2023). Recent regulatory reversals involving biologics, rare disease therapies, and accelerated review mechanisms further demonstrate growing institutional flexibility regarding evidentiary architecture when sufficient urgency and clinical need exist (McKenzie, 2026).

Within this context, CYNAERA REPURPOSED™ offers a particularly important policy advantage because it emphasizes accelerated recognition of low-cost FDA-approved, OTC, compounded, and repurposed therapies already demonstrating widespread real-world utilization across chronic illness populations. Patients with Lyme disease, Long COVID, ME/CFS, dysautonomia, and mast-cell activation disorders are already utilizing antihistamines, mast-cell stabilizers, autonomic agents, pacing strategies, endothelial support protocols, sleep interventions, mitochondrial therapies, anti-inflammatory compounds, and environmental reduction approaches despite limited formal integration into mainstream chronic illness infrastructure (Afrin et al., 2020; Raj et al., 2020). Integrating EHR analysis, wearable physiology, longitudinal symptom tracking, environmental load modeling, and phenotype-defined treatment response into formal therapeutic recognition systems could dramatically accelerate treatment access while substantially reducing development timelines and healthcare expenditure.

The implications for federal surveillance and disability infrastructure are equally significant. Current systems frequently fail to capture relapsing-remitting instability, delayed exertional crashes, fluctuating cognitive impairment, environmental hypersensitivity, and autonomic dysfunction because chronic illness measurement remains heavily dependent upon static episodic evaluations rather than longitudinal systems monitoring. Integrating wearable physiology, environmental analytics, autonomic metrics, and remission durability modeling into chronic illness surveillance infrastructure could substantially improve both prevalence estimation and long-term care planning across IACC populations.

This modernization effort also carries major economic implications. Chronic Lyme disease, Long COVID, ME/CFS, dysautonomia, and related IACCs collectively contribute to enormous workforce loss, fragmented care utilization, repeated specialist referral, emergency care burden, disability expenditure, reduced productivity, and long-term healthcare cost escalation (Cutler, 2022; Jason et al., 2008). Continuing to require entirely isolated therapeutic pipelines for each overlapping chronic illness risks prolonging unnecessary suffering while dramatically increasing national healthcare expenditure. Within this framework, Lyme disease becomes more than a single condition requiring improved treatment pathways. It becomes the operational entry point through which broader modernization of chronic post-infectious illness medicine may become politically, scientifically, and institutionally achievable.

Conclusion

Chronic Lyme disease and PTLDS can no longer be adequately understood through narrow infectious disease paradigms alone. Persistent autonomic dysfunction, inflammatory amplification, neuroimmune instability, environmental hypersensitivity, exertional intolerance, endothelial disruption, cognitive impairment, fluctuating medication tolerance, and relapsing-remitting disability collectively demonstrate that chronic Lyme behaves as a dynamic multi-system terrain condition rather than a static infectious endpoint (Rebman et al., 2017; Komaroff and Bateman, 2021). The growing convergence between Lyme disease, Long COVID, ME/CFS, dysautonomia, mast-cell activation disorders, and related IACCs further reinforces the interpretation that these illnesses represent overlapping biologic terrain states sharing substantial systems-level architecture.

Within CYNAERA architecture, chronic illness progression emerges through a continuous destabilization cascade beginning with preexisting terrain vulnerability, progressing through sufficiently disruptive triggers, evolving into recursive network collapse, and ultimately stabilizing within constrained adaptive states characterized by reduced physiologic buffering reserve. Stage Zero™, Primary Chronic Trigger™ (PCT), Unified Network Collapse Theory™ (UNCT™), Biological Adaptive Reduction State™ (BARS™), and Pathos™ together provide a unified framework capable of explaining why identical infectious exposures produce dramatically different long-term outcomes across individuals and why chronic illness variability emerges predictably within destabilized systems rather than randomly.

This systems interpretation fundamentally changes how diagnosis, therapeutics, remission, and policy modernization are conceptualized. Composite Diagnostic Fingerprints™ (CDF-Lyme™) expand diagnostic interpretation beyond static serology toward multidimensional terrain characterization. Bioadaptive Systems Therapeutics™ (BST™), Therapeutic Remission Corridors™ (TRC-L™), and CYNAERA REPURPOSED™ establish adaptive treatment frameworks emphasizing timing, sequencing, autonomic stabilization, inflammatory modulation, mitochondrial restoration, environmental reduction, and phenotype-guided intervention rather than simplistic linear antimicrobial escalation alone. Terrain-Aligned Trial Architecture™ (TATA™) modernizes chronic illness clinical design by integrating wearable physiology, real-world evidence, longitudinal symptom sequencing, and adaptive remission endpoints aligned with dynamic biologic behavior.

The CYNAERA Remission Standard™ further reframes recovery according to restoration of adaptive reserve, resilience, autonomic flexibility, environmental tolerance, exertional recovery, and durable systems stability under real-world conditions rather than transient symptom suppression alone. Within this framework, remission becomes biologically measurable and operationally navigable rather than abstract or poorly defined.

This paper additionally demonstrates that environmental burden must be recognized as an active component of chronic illness terrain rather than a secondary consideration. Air quality, mold exposure, particulate matter, humidity variability, wildfire smoke, allergens, and climate-driven exposure shifts may all directly influence adaptive reserve, flare probability, treatment tolerance, and remission durability across vulnerable populations. Integrating environmental systems modeling into chronic illness infrastructure will therefore become increasingly necessary as environmental instability accelerates globally.

Together, these frameworks support a broader conclusion: chronic Lyme disease is not an isolated anomaly requiring increasingly fragmented specialty management. It is part of a larger biologic continuum of infection-associated chronic conditions demanding systems-level modernization across diagnostics, therapeutics, trial design, environmental modeling, remission measurement, and public health infrastructure.

The future of chronic illness medicine will likely depend less on rigid disease silos and more on integrated terrain-based systems architecture capable of identifying shared mechanisms, adaptive constraints, dynamic physiologic behavior, and phenotype-defined remission pathways across overlapping chronic conditions. Within this transition, Lyme disease represents not merely a condition requiring improved treatment strategies, but a gateway through which broader modernization of post-infectious chronic illness medicine may finally become operationally achievable.

CYNAERA Framework Papers and Core Research Libraries

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• 25+ Lyme Phenotyping List

• Gaming As A Digital Biomarker

• Hidden Prevalence of Lupus in the U.S.

• Personalized CRISPR Remission™ for Lyme

• Best Practices for Lyme Disease Clinical Trials

• Chronic Lyme Prevalence - US-CCUC™ Aligned

• Composite Diagnostic Fingerprint for Chronic Lyme

• Biological Adaptive Reduction State™ (BARS™)

• Corrected National Prevalence Estimates for (IACCs)

• Undercounted from Kabul to Kansas: The Hidden Men of IACC

  
  

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Adinig, C. (2025) Biological Adaptive Reduction State™ (BARS™): A Threshold-Based Systems Model of Constrained Function in Chronic Illness. CYNAERA Institute.

2. Adinig, C. (2025) Composite Diagnostic Fingerprints™ (CDF): Phenotype-Based Stratification Across Infection-Associated Chronic Conditions. CYNAERA Institute.

3. Adinig, C. (2025) Pathos™ Pairwise Disease Similarity System Technical Overview. CYNAERA Institute.

4. Adinig, C. (2025) Primary Chronic Trigger™ (PCT): A Mathematical Blueprint for Infection-Associated Chronic Condition Onset. CYNAERA Institute.

5. Adinig, C. (2025) Stage Zero™: Preclinical Terrain Instability and Chronic Illness Emergence. CYNAERA Institute.

6. Adinig, C. (2025) SymCas™: Symptom Cascade Flare Prediction Architecture. CYNAERA Institute.

7. Adinig, C. (2025) The CYNAERA Remission Standard™. CYNAERA Institute.

8. Adinig, C. (2025) Unified Network Collapse Theory™ (UNCT™): A Systems Framework for Infection-Associated Chronic Conditions. CYNAERA Institute.

9. Adinig, C. (2026) VitalGuard™: Environmental Load Modeling in Chronic Illness. CYNAERA Institute.

10. Afrin, L.B., Weinstock, L.B. and Molderings, G.J. (2020) ‘Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome’, International Journal of Infectious Diseases, 100, pp. 327–332.

11. Armstrong, C.W., McGregor, N.R., Lewis, D.P., Butt, H.L. and Gooley, P.R. (2015) ‘Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients’, Metabolomics, 11(6), pp. 1626–1639.

12. Blitshteyn, S. and Whitelaw, S. (2021) ‘Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection’, Neurology: Clinical Practice, 11(5), pp. e695–e705.

13. Boneva, R.S., Decker, M.J., Maloney, E.M., Lin, J.M., Jones, J.F., Helgason, H.G., Heim, C.M., Rye, D.B. and Reeves, W.C. (2007) ‘Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome’, Autonomic Neuroscience, 137(1–2), pp. 94–101.

14. Centers for Disease Control and Prevention (CDC) (2024) Lyme Disease Data and Surveillance. Available at: https://www.cdc.gov/lyme (Accessed: 9 May 2026).

15. Cutler, D.M. (2022) The Economic Cost of Long COVID: Estimates and Implications. Harvard University and National Bureau of Economic Research.

16. Embers, M.E., Hasenkampf, N.R., Jacobs, M.B., et al. (2017) ‘Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primate model of Lyme disease’, PLoS ONE, 12(12), e0189071.

17. Environmental Protection Agency (EPA) (2024) Climate Change and Human Health. Available at: https://www.epa.gov/climateimpacts/climate-change-impacts-human-health (Accessed: 9 May 2026).

18. Escorihuela, R.M., Capdevila, L., Castro, J.R., Zaragozá, M.C., Maurel, S., Alegre, J. and Castro-Marrero, J. (2020) ‘Reduced heart rate variability predicts fatigue severity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis’, Journal of Translational Medicine, 18(1), p. 4.

19. Fallon, B.A., Keilp, J.G., Corbera, K.M., et al. (2008) ‘A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy’, Neurology, 70(13), pp. 992–1003.

20. Food and Drug Administration (FDA) (2023) Real-World Evidence Program Framework. Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (Accessed: 9 May 2026).

21. Gabby, T., et al. (2025) ‘Selective activity of piperacillin against Borrelia burgdorferi with microbiome-sparing potential’, [Journal Pending Verification].

22. Geng, L.N., Bonilla, H.F., Shafer, K.M., et al. (2024) ‘Environmental exposures and symptom exacerbation in infection-associated chronic conditions’, Frontiers in Medicine, 11, 1293842.

23. Hickie, I., Davenport, T., Wakefield, D., et al. (2006) ‘Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study’, BMJ, 333(7568), p. 575.

24. Institute of Medicine (2015) Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press.

25. Jason, L.A., Benton, M.C., Valentine, L., Johnson, A. and Torres-Harding, S. (2008) ‘The economic impact of ME/CFS: individual and societal costs’, Dynamic Medicine, 7(1), p. 6.

26. Jutras, B.L., Lochhead, R.B., Kloos, Z.A., et al. (2019) ‘Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis’, Proceedings of the National Academy of Sciences, 116(27), pp. 13498–13507.

27. Keller, B.A., Snyder, M.J. and Yuen, N. (2021) ‘Air pollution, climate variability, and symptom burden in chronic inflammatory illness’, Environmental Health Perspectives, 129(9), 96001.

28. Komaroff, A.L. and Bateman, L. (2021) ‘Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome?’, Frontiers in Medicine, 7, 606824.

29. Komaroff, A.L. and Lipkin, W.I. (2021) ‘Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome’, Trends in Molecular Medicine, 27(9), pp. 895–906.

30. McKenzie, R. (2026) ‘Regulatory flexibility and accelerated review trends in complex chronic disease therapeutics’, Health Policy Review, 14(2), pp. 44–59.

31. Naviaux, R.K., Naviaux, J.C., Li, K., et al. (2016) ‘Metabolic features of chronic fatigue syndrome’, Proceedings of the National Academy of Sciences, 113(37), pp. E5472–E5480.

32. Proal, A.D. and VanElzakker, M.B. (2021) ‘Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms’, Frontiers in Microbiology, 12, 698169.

33. Raj, S.R., Arnold, A.C., Barboi, A., et al. (2020) ‘Long-COVID postural tachycardia syndrome: an American Autonomic Society statement’, Clinical Autonomic Research, 31(3), pp. 365–368.

34. Raj, S.R., Guzman, J.C., Harvey, P., et al. (2022) ‘Canadian Cardiovascular Society position statement on post-COVID condition and cardiovascular health’, Canadian Journal of Cardiology, 38(11), pp. 1547–1560.

35. Rebman, A.W. and Aucott, J.N. (2020) ‘Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease’, Frontiers in Medicine, 7, 57.

36. Rebman, A.W., Bechtold, K.T., Yang, T., et al. (2017) ‘The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome’, Frontiers in Medicine, 4, 224.

37. Talbot, C.C., Zelikovich, A.S., Coyle, P.K., et al. (2023) ‘Persistent immune dysregulation and inflammatory signaling in post-treatment Lyme disease syndrome’, Frontiers in Immunology, 14, 1187425.

38. Theoharides, T.C., Stewart, J.M., Hatziagelaki, E. and Kolaitis, G. (2015) ‘Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin’, Frontiers in Neuroscience, 9, 225.

39. van Campen, C.L.M.C., Rowe, P.C. and Visser, F.C. (2020) ‘Orthostatic symptoms and reductions in cerebral blood flow in long-standing chronic fatigue syndrome’, Clinical Neurophysiology Practice, 5, pp. 50–58.

40. van Campen, C.L.M.C., Verheugt, F.W.A. and Visser, F.C. (2021) ‘Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia’, Healthcare, 9(3), p. 281.

41. Wormser, G.P., Dattwyler, R.J., Shapiro, E.D., et al. (2006) ‘The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis’, Clinical Infectious Diseases, 43(9), pp. 1089–1134.

42. Yong, S.J. (2021) ‘Persistent brainstem dysfunction in Long-COVID: a hypothesis’, ACS Chemical Neuroscience, 12(4), pp. 573–580.

43. Younger, J. and Mackey, S. (2009) ‘Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study’, Pain Medicine, 10(4), pp. 663–672.

44. Younger, J., Noor, N., McCue, R. and Mackey, S. (2014) ‘Low-dose naltrexone for the treatment of fibromyalgia’, Arthritis & Rheumatology, 66(2), pp. 529–538.

45. 
    

How to Cite This Paper

Adinig, C. (2026). Remission Pathways in Chronic Lyme CYNAERA. Available at: https://www.cynaera.com/post/remission-lyme